ARISTO
SME CapAristo Bio-Tech and Lifescience Ltd.
Pharma
Aristo Bio-Tech and Lifescience Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Investable fundamentals, management trust is supportive, price trend is neutral, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Average · 40/100Rev -4% YoY · PAT +200% YoY · margin expansion · operating leverage
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹107 Cr | -4.5% | -58.2% |
| EBITDA | ₹8 Cr | +700.0% | +0.0% |
| Operating margin | 8.0% | +700 bps | +500 bps |
| PAT | ₹3 Cr | +200.0% | -25.0% |
| PAT margin | 2.8% | +280 bps | +124 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Issuer presentation review pending
Aristo Bio-Tech and Lifescience Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trend score and candlestick chart
53NeutralSMA20 +8.3% / mo
Technical chart
ARISTOweekly · 5Y+30.1%Technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 40. Wait for confirmation.
- SMA20 rising (~7.7% over last month) — short-term momentum positive.
- RSI(14) at 40 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 34% off 52W high · 27% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
UNDERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- FCF yield is supportive at 7.4%.
- Piotroski is strong at 7/9.
- Fair-value margin of safety is positive at 78.7%.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 12/20; verify the latest quarterly trend.
- Balance sheet is weaker at 10/15; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 85th percentile of the scored universe and 77th percentile within Pharma. No major sub-score weakness stands out.
High Trust Lite: Promoter holding is 73.4%.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Pharma: 77th pctile, median 70 · SME: 96th pctile, median 65
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 73.4%.
- ▸Promoter pledge is zero.
- ▸FCF yield is 6%.
- ▸4 years of positive FCF.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 9.41
- P/B
- 1.52
- EV/EBITDA
- 5.40
- Market Cap
- 67.60Cr
Profitability
- ROE
- 17.60%
- ROCE
- 19.50%
- ROA
- 4.52%
- Dividend Y
- 0.50%
Growth (CAGR)
- Revenue 5Y
- 17.00%
- EPS 5Y
- 46.00%
- Revenue 3Y
- 19.00%
- EPS 3Y
- 26.00%
Balance Sheet
- Debt/Equity
- 0.78
- Interest Coverage
- 4.00×
- Altman Z
- 3.51
- Book Value
- 65.40
Cash Flow
- FCF Yield
- 7.40%
- FCF Positive Y
- 5/5
- OCF
- 8.00 Cr
- EPS TTM
- 10.55
Shareholding
- Promoter Hold
- 73.42%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 36%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.